查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1951815

干癣药物市场分析及预测（至2035年）：依类型、产品类型、技术、应用、最终用户、剂型、给药途径及研发阶段划分

Psoriasis Drugs Market Analysis and Forecast to 2035: Type, Product, Technology, Application, End User, Form, Mode, Stage
出版日期: | 出版商: Global Insight Services | 英文 317 Pages | 商品交期: 3-5个工作天内

价格
简介目录

预计银屑病治疗市场将从2024年的388亿美元成长到2034年的1,018亿美元，复合年增长率约为10.4%。银屑病治疗市场涵盖旨在控制银屑病（一种慢性自体免疫皮肤病）的药物治疗。该市场包括生物製药、全身用药和局部用药，这些药物专门用于减轻发炎和抑制皮肤细胞增殖。生物製药和个人化医疗的创新正在推动市场扩张。患者群体不断扩大、公众意识提高以及医疗保健服务覆盖范围扩大，正在进一步推动市场成长，而改善患者预后和生活品质是重点。

银屑病治疗市场正经历显着成长，这主要得益于生物製药和标靶治疗的进步。生物製药是表现最佳的类别，其中单株抗体和TNF-α抑制剂特别突出，它们具有更高的疗效和安全性。小分子药物，特别是PDE4抑制剂，是成长第二大的类别，因其口服给药的便利性而日益受到欢迎。在生物製药领域，IL-17和IL-23抑制剂已成为关键的细分市场，为中重度干癣患者提供了更好的治疗效果。局部治疗领域依然重要，用于治疗轻度干癣的皮质类固醇和维生素D类似物保持稳定的需求。人们对个人化医疗和以患者为中心的治疗方法的日益关注正在推动创新，尤其是在优化治疗方法的联合治疗。生物相似药的兴起有望透过提高先进疗法的可及性和可负担性，进一步塑造市场格局。总体而言，在不断发展的治疗模式和未被满足的医疗需求的推动下，该市场预计将实现强劲成长。

市场区隔
类型 生物製药、小分子药物、生物相似药
产品 局部治疗、全身性用药、照光治疗、生物製药、口服治疗、注射、乳膏和软膏
科技 单株抗体、TNF抑制剂、IL-17抑制剂、IL-23抑制剂、Janus激酶抑制剂
适应症 斑块型干癣、水滴状干癣、内翻型干癣、脓疱型干癣、红皮症型干癣
最终用户 医院、诊所、居家医疗机构、研究机构
剂型 片剂、胶囊、液体、乳膏、软膏、凝胶、泡沫剂
给药途径 处方笺和非处方药
阶段 轻度干癣、中度干癣、重度干癣

银屑病治疗市场竞争激烈，许多市场参与者透过策略定价和创新产品上市来扩大市场份额。新型生物製药和生物相似药的推出正在重塑市场竞争格局，并因其高效性和安全性而备受关注。各公司正透过专注于成本效益高的生产和标靶治疗来策略性地定位自身，以满足日益增长的个人化医疗需求。在这个充满活力的市场中，以患者为中心的治疗模式正在推动治疗方案的显着进步。银屑病治疗市场的竞争异常激烈，主要参与者不断进行标竿管理以保持竞争优势。监管，尤其是在北美和欧洲，在确保安全性和有效性标准以及塑造市场动态发挥关键作用。银屑病患病率的不断上升进一步影响市场，推动了对先进治疗方法的需求。亚太地区的新兴市场由于医疗保健投资和意识的不断提高而提供了盈利的机会。儘管面临监管障碍和高昂的研发成本等挑战，但在创新和策略联盟的推动下，市场前景仍然光明。

主要趋势和驱动因素：

银屑病治疗市场正经历蓬勃发展，这主要得益于几个关键趋势和驱动因素。其中一个显着趋势是全球银屑病患者数量的不断增长，从而带动了对有效治疗方法的需求。人们对银屑病的认识不断提高，促使更多患者寻求医疗干预，进一步扩大了市场规模。此外，生物製药疗法的进步正在革新银屑病的治疗模式。生物製药具有标靶作用，副作用较少，因此成为医疗服务提供者的首选。生物相似药的推出也透过提供经济有效的替代方案，推动了市场扩张。此外，个人化医疗也备受关注，旨在提高治疗效果并改善患者预后。製药公司持续加大研发投入，开发满足个别病患需求的客製化疗法。随着我们对银屑病遗传和分子因素的认识不断加深，这一趋势预计将持续下去。此外，监管支持和加快药物核准也推动了市场成长。政府机构日益认识到创新治疗方法的必要性，从而加快了核准流程，并促进了药物创新。受上述因素综合影响，预计未来几年银屑病治疗市场将稳定成长。

目录

第一章执行摘要

第二章 市集亮点

第三章 市场动态

  • 宏观经济分析
  • 市场趋势
  • 市场驱动因素
  • 市场机会
  • 市场限制
  • 复合年均成长率：成长分析
  • 影响分析
  • 新兴市场
  • 技术蓝图
  • 战略框架

第四章 细分市场分析

  • 市场规模及预测：依类型
    • 生物製药
    • 小分子药物
    • 生物相似药
  • 市场规模及预测：依产品划分
    • 局部治疗
    • 全身用药
    • 照光治疗
    • 生物製药
    • 口服治疗
    • 注射
    • 奶油
    • 软膏
  • 市场规模及预测：依技术划分
    • 单株抗体
    • TNF抑制剂
    • IL-17抑制剂
    • IL-23抑制剂
    • Janus激酶抑制剂
  • 市场规模及预测：依应用领域划分
    • 斑块型干癣
    • 水滴状干癣
    • 反向型干癣
    • 脓疱型干癣
    • 红皮病型干癣
  • 市场规模及预测：依最终用户划分
    • 医院
    • 医疗设施
    • 居家医疗环境
    • 研究所
  • 市场规模及预测：依类型
    • 药片
    • 胶囊
    • 液体
    • 奶油
    • 软膏
    • 凝胶
    • 形式
  • 市场规模及预测：依管理途径
    • 处方药
    • 非处方药
  • 市场规模及预测：依发展阶段划分
    • 轻度干癣
    • 中度银屑病
    • 重度干癣

第五章 区域分析

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地区
  • 亚太地区
    • 中国
    • 印度
    • 韩国
    • 日本
    • 澳洲
    • 台湾
    • 亚太其他地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 义大利
    • 其他欧洲地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非
    • 撒哈拉以南非洲
    • 其他中东和非洲地区

第六章 市场策略

  • 需求与供给差距分析
  • 贸易和物流限制
  • 价格、成本和利润率趋势
  • 市场渗透率
  • 消费者分析
  • 法规概述

第七章 竞争讯息

  • 市场定位
  • 市场占有率
  • 竞争基准
  • 主要企业的策略

第八章 公司简介

  • Dermavant Sciences
  • Arcutis Biotherapeutics
  • UCB Pharma
  • Almirall
  • Leo Pharma
  • Celgene
  • Sun Pharmaceutical Industries
  • Glenmark Pharmaceuticals
  • Dr. Reddy's Laboratories
  • Eli Lilly and Company
  • Amgen
  • Novartis
  • Abb Vie
  • Janssen Pharmaceuticals
  • Bristol Myers Squibb
  • Pfizer
  • Sanofi
  • Biogen
  • Merck
  • Takeda Pharmaceutical Company

第九章：关于我们

简介目录
Product Code: GIS32470

Psoriasis Drugs Market is anticipated to expand from $38.8 billion in 2024 to $101.8 billion by 2034, growing at a CAGR of approximately 10.4%. The Psoriasis Drugs Market encompasses pharmaceutical treatments aimed at managing psoriasis, a chronic autoimmune skin condition. This market includes biologics, systemic agents, and topical treatments tailored to reduce inflammation and slow skin cell growth. Innovations in biologic drugs and personalized medicine are propelling market expansion. Increasing prevalence, awareness, and healthcare access are further driving growth, with a focus on improving patient outcomes and quality of life.

The Psoriasis Drugs Market is experiencing significant growth, propelled by advancements in biologics and targeted therapies. The biologics segment is the top-performing category, driven by monoclonal antibodies and TNF-alpha inhibitors, which offer improved efficacy and safety profiles. Small molecules, particularly PDE4 inhibitors, are the second highest-performing segment, gaining traction due to oral administration and convenience. Within biologics, IL-17 and IL-23 inhibitors are emerging as leading sub-segments, offering enhanced outcomes for patients with moderate to severe psoriasis. The topical treatments segment remains relevant, with corticosteroids and vitamin D analogs maintaining steady demand for mild cases. The growing focus on personalized medicine and patient-centric approaches is fostering innovation, particularly in combination therapies that optimize treatment regimens. The rise of biosimilars is anticipated to further shape the market landscape, increasing accessibility and affordability of advanced therapies. Overall, the market is poised for robust expansion, driven by evolving treatment paradigms and unmet clinical needs.

Market Segmentation
TypeBiologics, Small Molecules, Biosimilars
ProductTopical Therapies, Systemic Medications, Phototherapy, Biologics, Oral Treatments, Injectables, Creams, Ointments
TechnologyMonoclonal Antibodies, TNF Inhibitors, IL-17 Inhibitors, IL-23 Inhibitors, Janus Kinase Inhibitors
ApplicationPlaque Psoriasis, Guttate Psoriasis, Inverse Psoriasis, Pustular Psoriasis, Erythrodermic Psoriasis
End UserHospitals, Clinics, Homecare Settings, Research Institutes
FormTablets, Capsules, Liquids, Creams, Ointments, Gels, Foams
ModePrescription, Over-the-Counter
StageMild Psoriasis, Moderate Psoriasis, Severe Psoriasis

The Psoriasis Drugs Market is characterized by a diverse array of market players, each vying for a larger share through strategic pricing and innovative product launches. The competitive landscape is shaped by the introduction of novel biologics and biosimilars, which are gaining traction due to their enhanced efficacy and safety profiles. Companies are strategically positioning themselves by focusing on cost-effective production and targeted therapies, catering to a growing demand for personalized medicine. This dynamic market is witnessing a shift towards more patient-centric approaches, driving significant advancements in treatment options. Competition within the Psoriasis Drugs Market is intense, with key players constantly benchmarking to maintain a competitive edge. Regulatory influences, particularly in North America and Europe, play a pivotal role in shaping market dynamics, ensuring safety and efficacy standards. The market is further influenced by an increasing prevalence of psoriasis, driving demand for advanced therapeutics. Emerging markets in Asia-Pacific present lucrative opportunities, with rising healthcare investments and awareness. The market's future is promising, driven by innovation and strategic collaborations, despite challenges such as regulatory hurdles and high development costs.

Geographical Overview:

The Psoriasis Drugs Market is witnessing substantial growth across various regions, each presenting unique opportunities. North America dominates the market, driven by a high prevalence of psoriasis and advanced healthcare infrastructure. The region's focus on innovative therapies and significant investment in research and development further bolsters its market leadership. Europe follows, with a strong emphasis on biologics and biosimilars, supported by robust healthcare systems and patient awareness initiatives. In Asia Pacific, the market is expanding rapidly, propelled by increasing healthcare expenditure and rising awareness of psoriasis treatments. Countries like China and India are emerging as lucrative markets due to their large patient populations and improving access to healthcare services. Latin America and the Middle East & Africa are also gaining traction, with growing healthcare investments and increasing adoption of novel therapies. Brazil and South Africa are key emerging countries, showcasing potential for growth in psoriasis drug adoption and market penetration.

The global psoriasis drugs market is intricately influenced by tariffs, geopolitical risks, and evolving supply chain dynamics. In Japan and South Korea, heightened trade tensions with Western economies prompt a strategic pivot towards self-reliance in pharmaceutical R&D and manufacturing. China, facing external pressures, accelerates its domestic production capabilities and regulatory reforms to maintain market stability. Taiwan, while pivotal in biotech innovation, navigates geopolitical uncertainties with strategic alliances. The overarching market for psoriasis drugs is witnessing robust growth, driven by increasing prevalence and advanced biologics. By 2035, the market is anticipated to flourish, contingent on harmonized regulatory frameworks and resilient supply chains. Middle East conflicts further compound global supply chains, potentially escalating raw material costs and impacting energy-dependent production processes.

Key Trends and Drivers:

The psoriasis drugs market is experiencing dynamic growth fueled by several key trends and drivers. One prominent trend is the increasing prevalence of psoriasis worldwide, which is leading to a growing demand for effective treatment options. As awareness of the condition rises, more patients are seeking medical intervention, thereby expanding the market. Furthermore, advancements in biologic therapies are revolutionizing treatment paradigms. Biologics offer targeted action with fewer side effects, making them a preferred choice among healthcare providers. The introduction of biosimilars is also driving market expansion by providing cost-effective alternatives to established biologic treatments. Additionally, there is a significant focus on personalized medicine, which is enhancing treatment efficacy and patient outcomes. Pharmaceutical companies are investing in research and development to create tailored therapies that address individual patient needs. This trend is expected to continue as the understanding of genetic and molecular factors in psoriasis deepens. Moreover, regulatory support and expedited drug approvals are facilitating market growth. Government agencies are increasingly recognizing the need for innovative treatments, leading to faster approval processes and encouraging pharmaceutical innovation. These factors collectively position the psoriasis drugs market for robust expansion in the coming years.

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Technology
  • 2.4 Key Market Highlights by Application
  • 2.5 Key Market Highlights by End User
  • 2.6 Key Market Highlights by Form
  • 2.7 Key Market Highlights by Mode
  • 2.8 Key Market Highlights by Stage

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Biologics
    • 4.1.2 Small Molecules
    • 4.1.3 Biosimilars
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Topical Therapies
    • 4.2.2 Systemic Medications
    • 4.2.3 Phototherapy
    • 4.2.4 Biologics
    • 4.2.5 Oral Treatments
    • 4.2.6 Injectables
    • 4.2.7 Creams
    • 4.2.8 Ointments
  • 4.3 Market Size & Forecast by Technology (2020-2035)
    • 4.3.1 Monoclonal Antibodies
    • 4.3.2 TNF Inhibitors
    • 4.3.3 IL-17 Inhibitors
    • 4.3.4 IL-23 Inhibitors
    • 4.3.5 Janus Kinase Inhibitors
  • 4.4 Market Size & Forecast by Application (2020-2035)
    • 4.4.1 Plaque Psoriasis
    • 4.4.2 Guttate Psoriasis
    • 4.4.3 Inverse Psoriasis
    • 4.4.4 Pustular Psoriasis
    • 4.4.5 Erythrodermic Psoriasis
  • 4.5 Market Size & Forecast by End User (2020-2035)
    • 4.5.1 Hospitals
    • 4.5.2 Clinics
    • 4.5.3 Homecare Settings
    • 4.5.4 Research Institutes
  • 4.6 Market Size & Forecast by Form (2020-2035)
    • 4.6.1 Tablets
    • 4.6.2 Capsules
    • 4.6.3 Liquids
    • 4.6.4 Creams
    • 4.6.5 Ointments
    • 4.6.6 Gels
    • 4.6.7 Foams
  • 4.7 Market Size & Forecast by Mode (2020-2035)
    • 4.7.1 Prescription
    • 4.7.2 Over-the-Counter
  • 4.8 Market Size & Forecast by Stage (2020-2035)
    • 4.8.1 Mild Psoriasis
    • 4.8.2 Moderate Psoriasis
    • 4.8.3 Severe Psoriasis

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Technology
      • 5.2.1.4 Application
      • 5.2.1.5 End User
      • 5.2.1.6 Form
      • 5.2.1.7 Mode
      • 5.2.1.8 Stage
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Technology
      • 5.2.2.4 Application
      • 5.2.2.5 End User
      • 5.2.2.6 Form
      • 5.2.2.7 Mode
      • 5.2.2.8 Stage
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Technology
      • 5.2.3.4 Application
      • 5.2.3.5 End User
      • 5.2.3.6 Form
      • 5.2.3.7 Mode
      • 5.2.3.8 Stage
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Technology
      • 5.3.1.4 Application
      • 5.3.1.5 End User
      • 5.3.1.6 Form
      • 5.3.1.7 Mode
      • 5.3.1.8 Stage
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Technology
      • 5.3.2.4 Application
      • 5.3.2.5 End User
      • 5.3.2.6 Form
      • 5.3.2.7 Mode
      • 5.3.2.8 Stage
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Technology
      • 5.3.3.4 Application
      • 5.3.3.5 End User
      • 5.3.3.6 Form
      • 5.3.3.7 Mode
      • 5.3.3.8 Stage
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Technology
      • 5.4.1.4 Application
      • 5.4.1.5 End User
      • 5.4.1.6 Form
      • 5.4.1.7 Mode
      • 5.4.1.8 Stage
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Technology
      • 5.4.2.4 Application
      • 5.4.2.5 End User
      • 5.4.2.6 Form
      • 5.4.2.7 Mode
      • 5.4.2.8 Stage
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Technology
      • 5.4.3.4 Application
      • 5.4.3.5 End User
      • 5.4.3.6 Form
      • 5.4.3.7 Mode
      • 5.4.3.8 Stage
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Technology
      • 5.4.4.4 Application
      • 5.4.4.5 End User
      • 5.4.4.6 Form
      • 5.4.4.7 Mode
      • 5.4.4.8 Stage
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Technology
      • 5.4.5.4 Application
      • 5.4.5.5 End User
      • 5.4.5.6 Form
      • 5.4.5.7 Mode
      • 5.4.5.8 Stage
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Technology
      • 5.4.6.4 Application
      • 5.4.6.5 End User
      • 5.4.6.6 Form
      • 5.4.6.7 Mode
      • 5.4.6.8 Stage
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Technology
      • 5.4.7.4 Application
      • 5.4.7.5 End User
      • 5.4.7.6 Form
      • 5.4.7.7 Mode
      • 5.4.7.8 Stage
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Technology
      • 5.5.1.4 Application
      • 5.5.1.5 End User
      • 5.5.1.6 Form
      • 5.5.1.7 Mode
      • 5.5.1.8 Stage
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Technology
      • 5.5.2.4 Application
      • 5.5.2.5 End User
      • 5.5.2.6 Form
      • 5.5.2.7 Mode
      • 5.5.2.8 Stage
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Technology
      • 5.5.3.4 Application
      • 5.5.3.5 End User
      • 5.5.3.6 Form
      • 5.5.3.7 Mode
      • 5.5.3.8 Stage
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Technology
      • 5.5.4.4 Application
      • 5.5.4.5 End User
      • 5.5.4.6 Form
      • 5.5.4.7 Mode
      • 5.5.4.8 Stage
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Technology
      • 5.5.5.4 Application
      • 5.5.5.5 End User
      • 5.5.5.6 Form
      • 5.5.5.7 Mode
      • 5.5.5.8 Stage
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Technology
      • 5.5.6.4 Application
      • 5.5.6.5 End User
      • 5.5.6.6 Form
      • 5.5.6.7 Mode
      • 5.5.6.8 Stage
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Technology
      • 5.6.1.4 Application
      • 5.6.1.5 End User
      • 5.6.1.6 Form
      • 5.6.1.7 Mode
      • 5.6.1.8 Stage
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Technology
      • 5.6.2.4 Application
      • 5.6.2.5 End User
      • 5.6.2.6 Form
      • 5.6.2.7 Mode
      • 5.6.2.8 Stage
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Technology
      • 5.6.3.4 Application
      • 5.6.3.5 End User
      • 5.6.3.6 Form
      • 5.6.3.7 Mode
      • 5.6.3.8 Stage
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Technology
      • 5.6.4.4 Application
      • 5.6.4.5 End User
      • 5.6.4.6 Form
      • 5.6.4.7 Mode
      • 5.6.4.8 Stage
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Technology
      • 5.6.5.4 Application
      • 5.6.5.5 End User
      • 5.6.5.6 Form
      • 5.6.5.7 Mode
      • 5.6.5.8 Stage

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Dermavant Sciences
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Arcutis Biotherapeutics
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 UCB Pharma
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Almirall
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Leo Pharma
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Celgene
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Sun Pharmaceutical Industries
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Glenmark Pharmaceuticals
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Dr. Reddy's Laboratories
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Eli Lilly and Company
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Amgen
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Novartis
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Abb Vie
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Janssen Pharmaceuticals
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Bristol Myers Squibb
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Pfizer
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Sanofi
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Biogen
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Merck
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Takeda Pharmaceutical Company
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us